AVXL Anavex Life Sciences Corp

$AVXL (Part 1/2) - Serious historical governance failure: Management says Missling controlled too much regulatory/clinical information, limiting transparency to the CFO, Audit Committee and Board. This created a material weakness in internal controls and increased the risk that important information could be omitted from SEC disclosures. - New leadership is restructuring: Anavex is sharply narrowing its focus to blarcamesine (ANAVEX 2-73) for three indications: early Alzheimer’s, Rett syndrome and Fragile X. Other pipeline assets are paused or may be partnered/licensed/sold. - Alzheimer’s strategy is being reset with FDA: Anavex has submitted an AD IND and is conducting ADME/DDI studies. Historical clinical data has been submitted, but the FDA will determine how much of that data can support the future U.S. development/Phase 3 strategy.

$AVXL looking forward to this shit being over soon and avxl being back on track to some approval!! based on kelly‘s speech and the continuous presence of some sab members i am more optimistic again. fingers crossed

$AVXL I think the present board is super pissed. They've been humiliated and snookered by Missling. I think they are on a tear to repair their reputations, advance Anavex and help society. Yup. No question in my mind.

$AVXL I've been crazy busy with work this year so haven't been spending much time here, but still reading everyones messages when I can. I voted all White with my 121K shares. Hope everyone is well. I hate the stock price but I'm very optomistic about things moving forward. Good ridance to Missling!

$AVXL Blaming current clinical leadership for legacy trial gaps completely ignores the actual timeline. The missing ADME and DDI clinical pharmacology stems from how the broader Alzheimer's program was run under Missling's barebones model from 2015 through 2023. When Kellmeyer, Edwards, and Lopez-Talavera arrived in early 2024 to inject real regulatory rigor, they inherited an incomplete package on a rushed EMA clock. Running these ADME and DDI studies today does the foundational legwork that should have happened years ago, ensuring the company sits down with the FDA with clean data rather than repeating past missteps. That context explains why this exact trio are the sole company authors on the upcoming CTAD presentation alongside core SAB leaders Sabbagh, Gabelle, and Grimmer. The board installed them while Missling was still there, so when he failed and was ousted, a seasoned team was already in place to take the reins and execute.

$AVXL It has been a while since biology was discussed on the AVXL board. I look forward to hearing some of these terms again: - Blarcamesine - autophagy - mechanism of action - Sigma-1 receptor - Muscarinic-1,2,3,4 receptors - Orthosteric vs allosteric interactions - ABCLEAR1,2,3 - statistical significance and many many others … it’s almost time to fire up your computer again. … I hope someone steps in and ends the Iranian quagmire so you can get back to business . Terrie and team … Keep us in the loop (within the limits of the law), and we will have your back.

$AVXL Readimg the First 100 day piece and it sounds like a first term students business 101 Project at a low grade business school. The lofty goal of hiring a top line CEO with CNS background and industry connections that will leave a good job to lead a company with the baggage AVXL has after Missiling ain't gonna happen. A CEO like that would just have his company acquire AVXL (lower risk). Terri knows that she will ultimately be replaced, but I think she is setting the company up to be courted for a solid partner that could ultimately acquire AVXL. The rest of their proposals are common sense and the reconfigured AVXL BOD will be following a similar plan. They have been passive until now, but they aren't idiots. The tutes will vote with the BOD, the drama will be over and if Terri lives up to her commitments, Blarcamesine will be back on track. If she wasn’t comfotable with the science she wouldnt be back. Bold prediction on my part, but I am holding. Good luck to all longs.

$AVXL Hopefully this should put to rest any ideas that Terrie isn't doing anything. She's just not communicating with shareholders now, for a very specific reason, but clearly she has been hard at work and with all the clamoring going on about the abysmal communication in the past under Missling, which she is aware of, she is likely to start communicating--and much better than him, in many ways--as soon as she can (I'm thinking after they file their 10-qs).

$AVXL What's the lesson of the day? Yes, this should have happened 4 years ago, but didn't because of an incompetent unethical CEO who has now been replaced with someone who seems to know what they are doing. But the true lesson is: don't mess things up by introducing people from PVG who can't follow through and will likely gut the company and sell it for parts to enrich themselves! Vote White card. Change your vote if you already voted for anyone from PVG. Just one fox in the henhouse is enough to sink this ship, at a time when it's just righted itself. And keep in mind the current board did finally fire Missling and is responsible for the current progress, even before the proxy battle. And I correct what I said earlier about no communication from Terrie, because the PR today was communication; what I meant was full or more comprehensive communication, but for that I think we will get after the 10-qs are filed.

$AVXL New CEO just gave the best update I've ever seen over the 6+ years I've been following Anavex. 100 times better than the diseiving, misleading, obtuse Missling PR's. It was transparent, honest, and informative. Missling refused to flat out say they needed new p3 studies for Rett and Alzheimer's and wasted YEARS. New CEO isn't playing those games. Encouraging, albeit the journey remains long. The problem was never the efficacy. It was poor trial design and horrible management. Brighter days appear ahead.

$AVXL Had a lengthy call with Clint, asked about where he sees company in 5yr, sold to Lilly or Pfizer and on a beach collecting dividends. Readout on trials, didn't have an answer, stated the data is strong, and hopeful that FDA will potentially fast track AD, but also Rett and Fragile X will be quick trials. He came across as very optimistic. Yes I bought more.

$AVXL for those wondering abt the Alz trial and # of patients, duration, etc…just consider that ANVS…. -1a/1b totaled approx 35 patients for safety, tolerability, pharmacokinetics…met endpoints -ph2/3 was 350 patients for 12 weeks (YES, 12 weeks) and adas-cog and adcs-cgic did NOT meet endpoints… - And the FDA agreed for them to run Ph3 w 6mth interim look, 18mth total for 850 patients. Adas-Cog and ADL are endpoints. The 6 mth look will evaluate tau for possible accelerated nda for SYMPTOMS. Now, consider Anavex more trial data more patients, SUBSTANTIALLY more years of treatment OLE data supporting benefit of earlier treatment EMA feedback focused on # patients, SUBGROUPS, endpoints, duration, titration/stats Do you think Anavex is going to be requested to run a full out ph3? We shall see but more than likely it’s 500-750 abckear1 w abclear3 pre specified. 6mth look for accelerated based on atrophy / ab42/40 biomarkers. 18 mth total We will know very soon! GLTA

$AVXL Another proxy solicitation letter was filed by Anavex this morning. Regarding the 10-Qs filed after hours on Friday, they are still waiting on Nasdaq to formally issue its "Notice of Compliance / Matter Closed" letter. Looking ahead, I expect a larger corporate update to be issued this week ahead of proxy advisory meetings with ISS and Glass Lewis. https://www.sec.gov/Archives/edgar/data/1314052/000173112226001171/e7904_defa14a.htm

$AVXL Sorry to point out the obvious, but with the proxy battle it deserves repeating: the soon-to-be-christened moniker of most hated person in biotech is apt for Christopher Missling, given what he has done to this company and shareholders. Although we've hardly heard anything from the interim CEO (I guess for legal reasons, at least in part), it seems like she's doing a great job righting his wrongs. We should keep PVG a million miles away from this company unless you want Missling's tentacles back in the mix given what appears to be their close connection. I’m not claiming fraud without evidence, but the combination of no prior CHMP scientific advice, the scathing CHMP report, and the new disclosure-control admissions makes Missling’s repeated optimism about the EMA path look profoundly misleading. With him now suing the company, what we appear to have is a man so consumed by greed, incompetence, ego, and a staggering lack of a moral compass that I pray we can soon right this ship.

$AVXL If the BoD were concerned that Missling might prevail in his wrongful termination suit they would not have reversed out all the non-stock cash compensation, holding some back in reserve just in case. This tells me they are confident Missling won't win in arbitration. One less thing to worry about. Now just focus on getting the FDA everything they need so they can start a P3 targeting ABCLEAR cohorts.

$AVXL The following highlighted paragraph from the June 2026 10-Q should be interesting to most Anavex investors.

$AVXL Anavex's outstanding 10-Qs have been filed alongside amendments to the prior two periods. Good to finally have this administrative overhang cleared. A Gemini-assisted breakdown of the four filings: "The scope of the review was limited to executive conduct, governance controls, and stock-based compensation adjustments. The company’s clinical pipeline, trial data, and stated balance sheet were not subject to operational revision and remain unaffected."

$AVXL Meeting with FDA, sounds like they are able to add pediatric group so that is good.

$AVXL for those without perspective of competition, Lilly gained 15-20b market cap and Biogen/Easai 15-20b market cap at ph2 trial results. Went up from there as they progressed the MAB drugs to commercialization. Upon anavex/fda alignment on the regulatory path for ph3 (most likely accelerated in some form for abckear3) that’s likely a comparable point for Anavex and will lead to an uptick valuation. Ofc, Anavex won’t command the MAB premium (YET), but you can bet upon trial confirmation and announcement it’s valuation should be in the 20-30% range of the MAB market cap #s with far more upside as the trial moves forward. Then maybe factor in a potential partner and boom. Read carefully the news release some serious nuggets. Team is stepping through the regulatory gates in a disciplined and methodical Fashion. And wow, looks like the auditors and team have agreed on a clawback of options to report. Think the vote is leaning white and reducing ExCeo & PVG leverage?

$AVXL TK is sounding solid and confident - she's got the appropriate and needed skill set to turn this around.